Association comprising a ligand of alpha-2-delta and an SSRI and / or SNRI for the treatment of depression and anxiety disorders

"UNDERSTANDING A TURNING ASSOCIATION OF ALPHA-2-DELTA AND AN SSRI AND / OR SNRI FOR DEPRESSION TREATMENT AND ANXIETY DISORDERS". there is provided a method of treating depression in a mammal, including a human, as well as depression and a disease, disorder or concurrent state illustrated by, but not limited to anxiety, sleep disorder and post-traumatic stress disorder. The method comprises administering to the mammal an effective amount of a combination of active ingredients comprising a) a ligand of alpha-2delta (A2D) or a prodrug thereof, or a pharmaceutically acceptable salt of said ligand A2D or of said pro and-drug, selected active agents; (B) a selective serotonin reuptake inhibitor (SSRI) or a prodrug thereof or a pharmaceutically acceptable salt of said SSRI or said prodrug, (c) a selective inhibitor of noradrenaline reuptake (SNRI) or a prodrug or a pharmaceutically acceptable salt of said SNRI or said prodrug and mixtures of (b) and (c). It is also provided a pharmaceutical formulation comprising a therapeutically effective amount of (a) an A2D ligand or a pro-drug, or a pharmaceutically acceptable salt of said A2D ligand or said prodrug and active agents selected from; (B) an SSRI or a prodrug or a pharmaceutically acceptable salt of said SSRI or said prodrug, (c) an SNRI or prodrug thereof or a pharmaceutically acceptable salt of said SNRI or said pro- mixtures of drug and (b) and (c). Preferred active ingredients for the treatment and the pharmaceutical composition include pregabalin, gabapentin, sertraline and reboxetine.